<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Multidisciplinary Cancer Investigation</title>
<title_fa>نشریه بین المللی چند تخصصی سرطان</title_fa>
<short_title>Multidiscip Cancer Investig</short_title>
<subject>Medical Sciences</subject>
<web_url>http://mcijournal.com</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2476-4922</journal_id_issn>
<journal_id_issn_online>2538-1911</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.61882/mci</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1399</year>
	<month>7</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2020</year>
	<month>10</month>
	<day>1</day>
</pubdate>
<volume>4</volume>
<number>4</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Single Orbital Metastasis in Castration-Resistant Prostate Cancer</title>
	<subject_fa></subject_fa>
	<subject>Supportive and Palliative Care</subject>
	<content_type_fa></content_type_fa>
	<content_type>Case Report and Series</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-size:16px;&quot;&gt;&lt;span style=&quot;font-family:Times New Roman;&quot;&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Orbital metastasis of prostate cancer (PC) is very rare and even more unique in castration-resistant PC (CRPC). In this scenario, choline positron emission tomography/computed tomography (choline PET/CT) is the gold-standard restaging method of choice available in our setting, and new anti-androgens treatments show improvement in overall survival.&lt;br&gt;
&lt;strong&gt;Case presentation: &lt;/strong&gt;We report the case of a 69-year-old male patient diagnosed with PC, treated with radical prostatectomy, and salvage radiotherapy after biochemical recurrence. After new prostate-specific antigen (PSA) progression, androgen deprivation therapy (ADT) was started. Four and a half years later, and already labeled as non-metastatic CRPC with a negative extension study, including choline PET/CT, he developed an accidental left frontal head trauma, presenting with proptosis, palpebral oedema, and oculomotor disorder. Computed tomography (CT) and magnetic resonance imaging (MRI) showed a destructive bone lesion in the left orbit, associated with a soft tissue mass. These findings, suggestive of a neoplastic lesion, were histologically confirmed PC metastasis. Treatment was initiated with abiraterone, with a rapid improvement of symptoms, a progressive decrease of PSA, and a significant radiological response.&lt;br&gt;
&lt;strong&gt;Conclusion&lt;/strong&gt;: Orbital metastases may present with proptosis and should be considered in patients with a history of cancer. If the ocular-orbital disease is suspected, the nuclear medicine physician should be aware that the choline PET/CT imaging includes the orbits. Tolerability and response to treatment with abiraterone were excellent.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Prostatic Neoplasms, Orbital Neoplasms, Neoplasm Metastasis</keyword>
	<start_page>1</start_page>
	<end_page>4</end_page>
	<web_url>http://mcijournal.com/browse.php?a_code=A-10-363-1&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Sonia</first_name>
	<middle_name></middle_name>
	<last_name>García-Cabezas</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>songar1@gmail.com</email>
	<code>10031947532846002704</code>
	<orcid>10031947532846002704</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Radiation Oncology, Reina Sofia University Hospital, Cordoba, Spain</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>María del Carmen</first_name>
	<middle_name></middle_name>
	<last_name>Moreno-Manzanaro Moreno</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>morenomanzanaroma@gmail.com</email>
	<code>10031947532846002705</code>
	<orcid>10031947532846002705</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Radiation Oncology, Reina Sofia University Hospital, Cordoba, Spain</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Amalia</first_name>
	<middle_name></middle_name>
	<last_name>Palacios-Eito</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>amalia.palacios.sspa@juntadeandalucia.es</email>
	<code>10031947532846002706</code>
	<orcid>10031947532846002706</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Department of Radiation Oncology, Reina Sofia University Hospital, Cordoba, Spain</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
